1099570-25-8

Basic information

• Product Name: (6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate
• Synonyms: (6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate;benzyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate;(1S,4S,6R)-tert-Butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate
• CAS NO: 1099570-25-8
• Molecular Formula: C11H19NO3
• Molecular Weight: 213.27346
• Mol File: 1099570-25-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(1099570-25-8)
• EPA Substance Registry System: (6R)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(1099570-25-8)

Safety Data

• Hazardous Substances Data: 1099570-25-8(Hazardous Substances Data)

Usage

General Description

(6R)-Tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate is a chemical compound with a molecular structure containing a tert-butyl group and a carboxylate ester. It belongs to the class of azabicyclic compounds and is in the (6R) configuration, indicating the stereoisomerism of the molecule. The presence of the hydroxy group on the 6th position of the azabicyclo[2.2.1]heptane ring makes it a hydroxy ester derivative. (6R)-Tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate may have potential pharmacological applications due to its unique structure and properties, and further research and exploration are necessary to uncover its full potential.

Upstream product

• 1932285-09-0 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1099570-25-8 tert-butyl (1RS,4SR,6RS)-6-hydroxy-2-azabicyclo[2.2.1] heptane-2-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 542-92-7 cyclopenta-1,3-diene 
• 149494-50-8 (-)-(1S,1'R)-2-(1'-Phenylethyl)-2-azabicyclo<2.2.1>hept-5-ene 
• 702666-72-6 tert-butyl (1S,4R)-2-azabicyclo[2.2.1]heptan-5-en-2-carboxylate 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 1932285-09-0 (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 198835-01-7 (1S,4R,6S)-tert-butyl 6-hydroxy-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 188345-71-3 2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene 

Downstream Products

• 1932285-09-0 tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1005077-74-6 exo-6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1005077-74-6 endo-6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1932285-09-0 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1932285-09-0 (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 1099570-25-8 (1S,4R,6R)-tert-butyl 6-hydroxy-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 1099570-25-8 tert-butyl (1RS,4SR,6SR)-6-hydroxy-2-azabicyclo[2.2.1] heptane-2-carboxylate 
• 1005077-74-6 (1S,4S,6R)-tert-butyl 6-amino-2-azabicyclo[2,2,1]heptane-2-carboxylate 

Relevant articles and documents

Synthesis of novel azanorbornylpurine derivatives

Azanorbornylpurine derivatives were prepared by Mitsunobu reaction of appropriate hydroxyazanorbornane derivative with 6-chloropurine or construction of purine base at azanorbornylamines. The prepared target compounds were evaluated for antiviral activity and effect on neuronal and muscle nicotinic acetylcholine receptors.

FXR RECEPTOR AGONIST

The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester, wherein

SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.